Intellia Therapeutics (NTLA) News Today $8.44 -0.40 (-4.52%) Closing price 04:00 PM EasternExtended Trading$8.38 -0.06 (-0.77%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Intellia Therapeutics (NTLA) Expected to Announce Earnings on ThursdayIntellia Therapeutics (NASDAQ:NTLA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-intellia-therapeutics-inc-stock/)May 3 at 5:06 AM | marketbeat.comStifel Financial Corp Buys 303,151 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Stifel Financial Corp raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 320.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 397,761 shares of the company'sMay 3 at 4:19 AM | marketbeat.comMarshall Wace LLP Invests $1.11 Million in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Marshall Wace LLP acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 95,339 shares of the company's stock, valued at apMay 2 at 3:52 AM | marketbeat.comRenaissance Technologies LLC Purchases New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Renaissance Technologies LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 98,700 shares of the company's stock, valued at approximatelyMay 2 at 3:33 AM | marketbeat.comIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company UpdatesMay 1, 2025 | finance.yahoo.comPDT Partners LLC Buys 312,794 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)PDT Partners LLC increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2,111.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 327,608 shares of the cMay 1, 2025 | marketbeat.comIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company UpdatesMay 1, 2025 | globenewswire.comAquatic Capital Management LLC Raises Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Aquatic Capital Management LLC raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 98.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 182,434 shares of the company's stoMay 1, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Should You Buy?Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's WhyApril 30, 2025 | marketbeat.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtApril 30, 2025 | fool.comRaymond James Financial Inc. Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Raymond James Financial Inc. purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 411,077 shares of the company's stock, valuedApril 28, 2025 | marketbeat.comFY2025 Earnings Estimate for NTLA Issued By Zacks ResearchIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Investment analysts at Zacks Research increased their FY2025 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a report issued on Tuesday, April 22nd. Zacks Research analyst R. Department now expects that the companApril 27, 2025 | marketbeat.comFY2025 Earnings Forecast for NTLA Issued By Zacks ResearchApril 27, 2025 | americanbankingnews.comBank of Montreal Can Purchases New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Bank of Montreal Can acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 35,586 shares of the company's stock, valued at approximately $415,000. A numberApril 25, 2025 | marketbeat.comWells Fargo & Company MN Purchases 76,872 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Wells Fargo & Company MN increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 38.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 277,692 shares of the company's stock after purchasing an additional 76,872 shares duApril 25, 2025 | marketbeat.comLawsuit for Investors in shares of Intellia Therapeutics, Inc. ...April 23, 2025 | gurufocus.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 10.1% - Still a Buy?Intellia Therapeutics (NASDAQ:NTLA) Trading 10.1% Higher - Here's WhyApril 23, 2025 | marketbeat.comLawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders FoundationApril 23, 2025 | prnewswire.comWolfe Research Upgrades Intellia Therapeutics (NASDAQ:NTLA) to OutperformWolfe Research raised shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a research report on Monday.April 23, 2025 | marketbeat.comWolfe Research Upgrades Intellia Therapeutics (NTLA)April 22, 2025 | msn.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Rockefeller Capital Management L.P.Rockefeller Capital Management L.P. grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 81.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 137,838 shares of the company'April 22, 2025 | marketbeat.comRussell Investments Group Ltd. Has $1.37 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Russell Investments Group Ltd. lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 40.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,415 shares of the companApril 22, 2025 | marketbeat.comIntellia Therapeutics upgraded at Wolfe on sentiment, valuationApril 21, 2025 | markets.businessinsider.comFederated Hermes Inc. Has $45,000 Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Federated Hermes Inc. lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 99.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,845 shares of the company's stock after sellingApril 21, 2025 | marketbeat.comGeode Capital Management LLC Increases Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Geode Capital Management LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,389,240 shares of the company's stock aApril 20, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Jump Financial LLCJump Financial LLC raised its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 362,637 shares of the company's stock after buApril 19, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 4.9% - Should You Sell?Intellia Therapeutics (NASDAQ:NTLA) Trading Down 4.9% - Time to Sell?April 18, 2025 | marketbeat.comAlliancebernstein L.P. Lowers Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Alliancebernstein L.P. reduced its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 87.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 265,318 shares of the company's stockApril 17, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesIntellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nineteen research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recApril 16, 2025 | marketbeat.comIntellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLAApril 15, 2025 | globenewswire.comFIL Ltd Grows Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)FIL Ltd boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 737.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 159,671 shares of the company's stock after acquiring an additional 140,608 shares durApril 15, 2025 | marketbeat.comNTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.April 15, 2025 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLAApril 14, 2025 | prnewswire.comNTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 14, 2025 | globenewswire.comNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. ...April 14, 2025 | gurufocus.comNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 14, 2025 | businesswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia TherapeuticsApril 14, 2025 | tmcnet.comFinal Deadline Today for the Intellia Therapeutics, Inc. ...April 14, 2025 | gurufocus.comFinal Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLAApril 14, 2025 | prnewswire.comNTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. ...April 14, 2025 | gurufocus.comNTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 14, 2025 | prnewswire.comNTLA Deadline: NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. ...April 13, 2025 | gurufocus.comNTLA Deadline: NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud LawsuitApril 13, 2025 | prnewswire.comNTLA Investors Have the Opportunity to Lead the Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLPApril 13, 2025 | globenewswire.comFINAL NTLA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Intellia Therapeutics, Inc. Investors to Join the Class Action LawsuitApril 13, 2025 | markets.businessinsider.comWellington Management Group LLP Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Wellington Management Group LLP increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 699,814 shares of the company's stock after purchasing an additionalApril 13, 2025 | marketbeat.comTMDX DEADLINE TUESDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages TransMedics Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 15 Deadline in Securities Class Action First Filed by the Firm – TMDXApril 12, 2025 | globenewswire.comExodusPoint Capital Management LP Acquires 52,486 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)ExodusPoint Capital Management LP increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 98.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,827April 12, 2025 | marketbeat.comIntellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ...April 11, 2025 | gurufocus.comSemtech Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. April 22, 2025 Deadline to file Lead Plaintiff MotionApril 11, 2025 | globenewswire.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.840.72▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼1111▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SpringWorks Therapeutics News Akero Therapeutics News Organon & Co. News Merus News Crinetics Pharmaceuticals News Scholar Rock News Xenon Pharmaceuticals News Catalyst Pharmaceuticals News Viking Therapeutics News MorphoSys News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTLA Stock Free NTLA Stock Alerts